Drug intelligence / Profile preview

ID-082

Development stage: Unknown
Lead developer: Idorsia
Modality: Small Molecules
Administration: Oral

Overview

ID-082 is an investigational small molecule drug developed by Idorsia Pharmaceuticals. It has been studied in a Phase 1 clinical trial to assess its effect on the pharmacokinetics of midazolam and its metabolite 1-hydroxymidazolam in healthy male subjects. The specific mechanism of action, therapeutic area, and target(s) for ID-082 have not been publicly disclosed as of the latest available information. The primary focus so far has been on evaluating potential drug-drug interactions via effects on cytochrome P450 enzymes, as midazolam is a known CYP3A4 substrate[7].

Beyond the preview

Go deeper on ID-082.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ID-082.

Explore the full profile